June 18- Rite Aid Corp, the No.3 U.S. drugstore chain operator, reported slower-than-expected quarterly same-store sales growth as the introduction of new generic drugs hurt pharmacy sales. Net income more than halved to $18.8 million, or 2 cents per share, in the quarter, from $41.4 million, or 4 cents per share, a year earlier. The fall in net income was mainly due to...» Read More
Feb 11- Drugstore operator Rite Aid Corp said it would buy pharmacy benefit manager EnvisionRx for about $2 billion, to enter the business of administering drug benefits for employers. The third-largest U.S. drug-store chain said it would pay about $1.8 billion in cash and $200 million in stock. Rite Aid's shares rose 3 percent to $7.88 in premarket trading.
Feb 10- CVS Health Corp reported a better-than-expected quarterly net revenue, boosted by growth in its Medicaid business and strength in specialty drug sales. CVS became the first national drugstore chain in the United States to take cigarettes off its shelves from Oct. 1. CVS Health has focused on developing its specialty pharmacy business, which sells drugs...
Feb 10- CVS Health Corp, the No. 2 U.S. drugstore operator, reported a better-than-expected quarterly net revenue, helped by a jump in pharmacy same-store sales and strength in its specialty pharmacy business. CVS Health has focused on developing its specialty pharmacy business, which sells drugs to treat complex diseases such as multiple sclerosis, rheumatoid...
Mike Narachi, Orexigen CEO, speaks with CNBC's Meg Tirrell about its obesity drug and program.
Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.
SHANGHAI, Jan 9- China will allow online sales of prescription drugs as early as this month, a policy that will open up an over 1 trillion yuan market to online pharmacy operators like Alibaba Group Holding Ltd and Wal-Mart Stores Inc.. The policy would help reform a fragmented and opaque market controlled by state-run distributors and hospitals, brought into...
Jan 6- Walgreen Co, the largest U.S. pharmacy chain, reported a better-than-expected jump in December comparable store sales, helped by the month containing one more Wednesday and one fewer Sunday than a year ago and higher sales of flu medicine. Walgreen, which gets more than 60 percent of its revenue from prescription drug sales, also sells non-prescription...
CNBC's Jane Wells shares her top three predictions for the pot industry this year, including changing bank regulations and the beginning of voters' remorse where it's legal.
U.S. drugstore chain operator Walgreen reported a 16 percent rise in quarterly profit, helped by a record number of prescriptions filled.
Mark Fisher, MBF Clearing Corp. chairman, shares his favorite stock in the biotech space.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
Express Scripts Medical Chief Steve Miller, provides insight to his company's deal with AbbVie. The two companies have come to a deal which gives Express Scripts a significant discount on the hepatitis C drug.
CNBC's Meg Tirrell provides insight to a newly approved hepatitis C drug from AbbVie, which Express Scripts made an exclusive deal for a significant discount on the drug.
Intercept Pharmaceuticals CEO Mark Pruzanski, provides insight to his company's efforts to tackle NASH, or nonalcoholic steatohepatitis, saying over 10 percent of the U.S. population is thought to have NASH. Pruzanski also weighs in on being a public company.
Discussing warning signs from Dendreon, and other worrisome companies, with Les Funtleyder, E Square Asset Management.
Joseph Pantginis, Roth Capital, has been negative on Dendreon for a long time, ahead of the drugmaker's bankruptcy protection filing.
Kroger has delivered 43 straight quarters of rising sales at stores open at least a year.
Drug companies may be looking for legal protection amid a massive demand for Ebola vaccines, reports CNBC's Meg Tirrell.
Walgreen's former CFO sued the drugstore operator, alleging executives defamed him in news reports that blamed him for errors in its forecast.
GW Pharma shares are down sharply after a study of its treatment for ulcerative colitis missed its primary endpoint in a mid-stage trial. GW Pharmaceuticals CEO Justin Gover, says the company's main focus is on its product for epilepsy.